A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Prior treatment

• Major surgery (excluding placement of vascular access) within 4 weeks prior to first dose of CTX-712.

Other illness

• History of other malignancy.
• History of allogeneic organ transplantation (excluding cornea).
• History of allogenic hematopoietic stem cell transplantation within 6 months of planned study treatment initiation and/or graft-versus host disease grade ≥ 1 following allogenic hematopoietic stem cell transplantation.
• History of or chimeric antigen receptor T-cell therapy or other modified T cell therapy.
• Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus, hepatitis C virus, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness. Infections controlled with oral anti-infective agents, including prophylactic treatments, are allowed. Patient must be viral load negative.
• Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Lab values

• Any of the following cardiopulmonary abnormalities:
  • Myocardial infarction within six months prior to registration.
  • New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction \< 50%.
  • A history of familial long QT syndrome.
  • Symptomatic atrial or ventricular arrhythmias not controlled by medications.
  • QTcF ≥ 470 msec calculated according to institutional guidelines, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.
  • Known moderate to severe and clinically significant chronic obstructive pulmonary disease, interstitial lung disease and/or pulmonary fibrosis (e.g., requiring home oxygen therapy).

Other

• Diagnosis of acute promyelocytic leukemia.
• Isolated extramedullary relapse (phase 2 only).
• Active central nervous system (CNS) leukemia.
• Pregnancy and/or lactation.

• Age ≥18 years.
• Diagnosis of AML, HR-MDS, or high marrow blast MDS/MPN (including CMML). Note: Only patients with AML and HR-MDS are eligible in the expansion cohorts.
• Prior treatment history must include 1-4 prior lines of therapy. Note: 1-3 prior lines are allowed for patients in the expansion cohorts.
• Adequate organ function evidenced by the following laboratory values:
  • Creatinine clearance (CL) ≥60 mL/min
  • Total serum bilirubin \< 1.5 × upper limit of normal (ULN)
  • Alanine aminotransferase (ALT)
  • Aspartate aminotransferase(AST) \< 2.5 × ULN
  • White blood cell count at the time of the first dose \<10 k/μL
• Eastern Cooperative Oncology Group performance status ≤2.
• Female patients of childbearing potential must have a negative pregnancy test within 7 days before study treatment initiation and if sexually active, agree to use a highly effective form of contraception throughout their participation during study treatment and up to 4 months after the last dose of study drug.
• Male patients with female partners of childbearing potential must, even if surgically sterilized, agree to practice effective barrier contraception during the entire study treatment period and through four months after the last dose of study drug, or practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant.